@article {Alanio2020.05.18.20105296, author = {Alexandre Alanio and Sebastian Voicu and Sarah Delli{\`e}re and Bruno M{\'e}garbane and St{\'e}phane Bretagne}, title = {Do COVID-19 patients admitted to the ICU require anti-Pneumocystis jirovecii prophylaxis?}, elocation-id = {2020.05.18.20105296}, year = {2020}, doi = {10.1101/2020.05.18.20105296}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {We are currently facing a frightening increase in COVID-19 patients admitted to the ICU. Aiming at screening for secondary pneumonia, we collected the data of our first twelve ICU patients who underwent bronchoalveolar lavage (BAL). Surprisingly, four were detected with Pneumocystis jirovecii (Pj) DNA and RNA, resulting in Pj prevalence of 17\%. Pj is a ubiquitous ascomycetes fungus that thrives at the surface of type-I pneumocytes, specifically in human alveoli, leading to pneumocystosis in immunocompromised patients. Interestingly, none of our patients was immunocompromised per se before admission, while all presented the recognized risk factors for life-threatening COVID-19 infection. Observing such high prevalence in COVID-infected patients was unexpected. Almost all patients developed ARDS and received high-dose steroids to prevent worsening, as suggested by reports from China. In Pj-positive patients requiring steroids, prophylaxis was given to avoid the risk of pneumocystosis and increased lung inflammation that may compromise the outcome.We are strongly convinced that testing deep lung specimens for Pj in severe COVID-19 patients should be recommended and Pj-positive patients treated with steroids, and given anti-Pj prophylaxis. This message is important, given the high mortality rate of COVID-19 patients in the ICU.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was part of the French COVID-19 cohort registry conducted by the REACTing consortium (REsearch and ACTion targeting emerging infectious diseases) and directed by INSERM (Institut national de la sant{\'e} et de la recherche m{\'e}dicale) and ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium). Our institutional ethics committee approved the study (IDRCB, 2020-A00256-33; CPP, 11-20 20.02.04.68737). When possible, signed informed consent was obtained from the patients or the next of kin.Funding StatementThe case investigations, analysis, and manuscript preparation were completed as part of official duties at the university hospitalAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be foully available for the community}, URL = {https://www.medrxiv.org/content/early/2020/05/22/2020.05.18.20105296}, eprint = {https://www.medrxiv.org/content/early/2020/05/22/2020.05.18.20105296.full.pdf}, journal = {medRxiv} }